Jon Smith, reporter at Mergermarket, has published Mergermarket’s European CNS market review featuring insights from Ali Pashazadeh, Treehill Partners CEO, including that “…a growing understanding of the underlying pathology of Alzheimer’s is leading to … tailoring approaches to different forms of the condition. As a result, there will be exciting treatments emerging in the next ten years, and the huge costs of late stage development will likely require the resources of big pharma acquirers.”
Mergermarket is a renown subscription-based publication that caters to a large financial audience.
Read the full CNS market overview here (subscription required):